PHAXIAM Therapeutics Company Description

PHAXIAM Therapeutics S.A., a clinical-stage biopharmaceutical company, focuses on developing bacteriophage-based therapies for severe resistance infections in France.

The company develops and commercializes red cell-based therapies for cancers and orphan diseases. It develops anti-infectious therapies based on the use of bacteriophages (phages) to treat infections caused by Escherichia coli (E.coli), Pseudomonas aeruginosa (P.aeruginosa), and Staphylococcus aureus (S.aureus).

The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023.

The company was incorporated in 2004 and is headquartered in Lyon, France.

PHAXIAM Therapeutics S.A.

Country	France
Founded	2004
Industry	Biotechnology
Sector	Healthcare
Employees	68
CEO	Thibaut Fayet

Contact Details

Address: 60, avenue Rockefeller Lyon, 69008 France
Phone	33 4 78 74 44 38
Website	phaxiam.com

Stock Details

Ticker Symbol	PHXM
Exchange	Euronext Paris
Fiscal Year	January - December
Reporting Currency	EUR
ISIN Number	FR001400K4B1
SIC Code	2836

Key Executives

Name	Position
Dr. Jérôme Bailly Pharm.D.	Deputy Chief Executive Officer, Deputy GM, Chief Quality Officer and Qualified Person
Thibaut du Fayet	Chief Executive Officer
Frédéric Mathat	Chief Financial Officer
Cindy Fevre	Chief Scientific Officer
Naomi Eichenbaum	Director Investor Relations
Dr. Pascal Birman M.D.	Chief Medical Officer
Dr. Philip L. Lorenzi M.D., Ph.D.	Consultant and Member of Scientific Board
Prof. Eric Raymond M.D., Ph.D.	Consultant and Member of Scientific Board
Dr. Bridget Bax Ph.D.	Consultant and Member of Scientific Board
Prof. Arthur E. Frankel M.D., Ph.D.	Consultant and Member of Scientific Board